]>
IRCT20201027049164N6 IRCT 2022-03-29 Kerman University of Medical Sciences Investigation of the effect of artemisinin and Dermaneh and Afsantinin the treatment of coronavirus COVID-19 virus Investigation of the effect of artemisinin Capsules and Dermaneh (Artemisia persica)and Afsantin)Artemisia absinthium( Capsules in the treatment of coronavirus COVID-19 virus in Afzalipour hospital,kerman, 2020 2020-11-10 anticipated 30 Complete https://irct.ir/trial/51901 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: For randomization, the table of random numbers will be used. First, a code from 01 to 30, was given to patient. The first 15 was used for intervention group whereas the other15 for the control. We placed a finger on the columns of the random numbers table to determine start point, and the last two digits of each column were considered. It was ignored if numbers were higher For example, 23 code received placebo, Blinding description: Researchers, nurses, and patients will be not aware of medication or placebo because they will be similar in appearance. 3 COVID-19. Intervention 1: Intervention group: The intervention group will receive two Dermaneh capsules of artemisinin 100 mg, two capsules (each containing 5oo mg Dermaneh ) and two Dermaneh capsules (each containing 500 mg Afsantin) daily. Patients will be given daily capsules in packs containing 70capsules and we ask patients to take five capsules daily for 14 days. Intervention 2: Control group: The control group will receive placebo capsules daily. Patients will be given capsules in packs containing 84 capsules and we ask patients to take six capsules daily for 14 days. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is Undecided - It is not yet known if there will be a plan to make this available
public Masumeh Ghazanfarpour
Kerman University of Medical Sciences,Medical University Campus,Haft-Bagh Highway, Kerman, Ira
Kerman Iran (Islamic Republic of) 76169-13555 +98 34 3132 5700 masumeh.ghazanfarpour@yahoo.com Kerman University of Medical Sciences scientific Masumeh Ghazanfarpour
Kerman University of Medical Sciences,Medical University Campus,Haft-Bagh Highway, Kerman, Iran
Kerman Iran (Islamic Republic of) 7616913555 +98 34 3132 5856 Masumeh.ghazanfarpour@yahoo.com Kerman University of Medical Sciences Iran (Islamic Republic of) Patients with signing Informed Consent Age 18-65 years old Positive CRP test for SARS-CoV-2 virus or characteristic signs on a CT scan of the chest with mild to moderate clinical manifestations according to the National Early Warning Score (NEWS) (mild: 1-4 / moderate: 5-6) 18 years 65 years Both Receipt of any another experimental treatment Severe liver disease Known allergic reaction to drugs Severe renal disease Pregnant or breastfeeding women transfer to the intensive care unit U07.1 COVID-19, virus identified Treatment - Drugs Treatment - Drugs Intervention group: The intervention group will receive two Dermaneh capsules of artemisinin 100 mg, two capsules (each containing 5oo mg Dermaneh ) and two Dermaneh capsules (each containing 500 mg Afsantin) daily. Patients will be given daily capsules in packs containing 70capsules and we ask patients to take five capsules daily for 14 days. Control group: The control group will receive placebo capsules daily. Patients will be given capsules in packs containing 84 capsules and we ask patients to take six capsules daily for 14 days. Oxygen saturation. Timepoint: At the beginning (before the intervention) and 14 days after intervention. Method of measurement: Pulse Oximeter. Respiratory Rate. Timepoint: At the beginning of the study (before the intervention) and14 days after intervention. Method of measurement: Respiratory Count. C-reactive protein. Timepoint: At the beginning of the study (before the intervention) , 7 days after the intervention, 14 days after intervention. Method of measurement: Venous blood test. Lymphocytes. Timepoint: At the beginning of the study (before the intervention) and 14 days after intervention. Method of measurement: Venous blood test. Headache. Timepoint: At the beginning of the study (before the intervention) and 14 days after the intervention. Method of measurement: Questionnaire. Muscle pain. Timepoint: At the beginning of the study (before the intervention) and 14 days after the intervention. Method of measurement: Questionnaire. Sore throat. Timepoint: At the beginning of the study (before the intervention) and 14 days after the intervention. Method of measurement: Questionnaire. Anorexia. Timepoint: At the beginning of the study (before the intervention) and 14 days after the intervention. Method of measurement: Questionnaire. Fatigue. Timepoint: At the beginning of the study (before the intervention)and 14 days after the intervention. Method of measurement: Questionnaire. Cough. Timepoint: At the beginning of the study (before the intervention) and 14 days after the intervention. Method of measurement: Questionnaire. Vice Chancellor for Research and Technology of Kerman University of Medical Sciences Approved 2020-10-24 Ethics committee of Kerman University of Medical Sciences Deputy of Research and Technology;ebne-e-Sina St.,Jahad Blvd., Kerman,Iran Kerman Kerman Iran (Islamic Republic of)